Another drug that inhibits the binding of PD-L1 to both PD-1 and CD80 is Nivolumab, IgG4 monoclonal antibody; it is also approved by the FDA for the treatment of R/M-HNSCC [12]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.